Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Biomarin Pharmaceuticals (BMRN)
Biomarin Pharmaceuticals (BMRN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 17,408,970
  • Shares Outstanding, K 188,368
  • Annual Sales, $ 2,096 M
  • Annual Income, $ 141,560 K
  • 60-Month Beta 0.40
  • Price/Sales 8.19
  • Price/Cash Flow 60.91
  • Price/Book 3.45
Trade BMRN with:

Options Overview Details

View History
  • Implied Volatility 23.74% ( +0.21%)
  • Historical Volatility 42.77%
  • IV Percentile 2%
  • IV Rank 4.71%
  • IV High 50.90% on 06/28/23
  • IV Low 22.40% on 11/03/23
  • Put/Call Vol Ratio 0.64
  • Today's Volume 526
  • Volume Avg (30-Day) 2,052
  • Put/Call OI Ratio 0.83
  • Today's Open Interest 36,647
  • Open Int (30-Day) 35,210

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 25 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/23
See More
  • Average Estimate 0.24
  • Number of Estimates 12
  • High Estimate 0.27
  • Low Estimate 0.19
  • Prior Year 0.11
  • Growth Rate Est. (year over year) +118.18%

Price Performance

See More
Period Period Low Period High Performance
1-Month
76.02 +21.57%
on 11/02/23
92.50 -0.09%
on 12/01/23
+8.41 (+10.01%)
since 11/01/23
3-Month
76.02 +21.57%
on 11/02/23
92.95 -0.57%
on 09/13/23
-0.61 (-0.66%)
since 09/01/23
52-Week
76.02 +21.57%
on 11/02/23
117.77 -21.53%
on 01/27/23
-10.60 (-10.29%)
since 12/01/22

Most Recent Stories

More News
4 Preeminent Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip

An 11% decline in the Nasdaq Composite over the past two years is an open invitation for opportunistic growth investors to go shopping.

COMP : 2.43 (+9.46%)
$NASX : 14,305.03 (+0.55%)
NIO : 7.15 (-1.65%)
OKTA : 73.63 (+9.81%)
BMRN : 92.42 (+1.47%)
BIDU : 116.77 (-1.59%)
3 Biotech Stocks Beating BioMarin Pharmaceutical (BMRN)

Breakthrough developments, the use of advanced technologies, and rising investments in R&D are some of the factors driving the growth of the biotech industry. Although BioMarin Pharmaceutical (BMRN) showcases...

AMGN : 272.45 (+1.04%)
BMRN : 92.42 (+1.47%)
JAZZ : 119.11 (+0.74%)
VRTX : 351.16 (-1.03%)
4 Unique Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip

A 19% decline in the Nasdaq Composite over the past two years represents an ideal time for opportunistic long-term investors to go shopping for bargains.

COMP : 2.43 (+9.46%)
$NASX : 14,305.03 (+0.55%)
GOOGL : 131.86 (-0.51%)
GOOG : 133.32 (-0.45%)
FSLY : 18.05 (+8.67%)
BMRN : 92.42 (+1.47%)
ETSY : 82.04 (+8.22%)
AMZN : 147.03 (+0.64%)
BioMarin: Q3 Earnings Snapshot

BioMarin: Q3 Earnings Snapshot

BMRN : 92.42 (+1.47%)
3 Under-the-Radar Biotech Stocks to Buy in 2023

These three lesser-known biotech companies are profitable and growing revenue.

AMLX : 14.22 (+0.42%)
BMRN : 92.42 (+1.47%)
EXEL : 21.94 (+0.60%)
BioMarin to Host Third-Quarter 2023 Financial Results Conference Call and Webcast on Wednesday, November 1, at 4:30pm ET

/PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will...

BMRN : 92.42 (+1.47%)
3 Biotech Stocks Showing Promising Returns for October

Technological advancements and the growing investment in developing healthcare infrastructures are expected to boost the biotech industry. Therefore, it could be wise to buy fundamentally strong biotech...

BMRN : 92.42 (+1.47%)
HALO : 39.69 (+2.80%)
UTHR : 240.73 (+0.30%)
3 Biotech Stocks Offering Potential for Gains

Solid foothold of personalized medicine, increasing prevalence of chronic diseases, favorable government initiatives, and rapid digital transformation are opening new avenues for biotech companies. Thus,...

BMRN : 92.42 (+1.47%)
EXEL : 21.94 (+0.60%)
SGIOY : 11.9300 (+1.71%)
Are Gene Therapy Stocks The Market's Next Big Winners?

Biotechs Sarepta and BioMarin are among companies advancing cutting-edge gene therapies, although those treatments can come with a $2 million or more price.

SRPT : 84.44 (+3.89%)
BMRN : 92.42 (+1.47%)
BIIB : 234.64 (+0.24%)
CRSP : 68.65 (+2.88%)
EDIT : 10.77 (+2.28%)
NTLA : 30.84 (+4.08%)
NVS : 98.13 (+0.23%)
ORTX : 16.21 (unch)
REGN : 814.86 (-1.09%)
SLDB : 3.01 (+6.74%)
BLUE : 4.26 (+11.52%)
4 Awe-Inspiring Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip

A nearly 15% decline in the growth-driven Nasdaq Composite from its record high is a blessing in disguise for opportunistic long-term investors.

COMP : 2.43 (+9.46%)
$NASX : 14,305.03 (+0.55%)
META : 324.82 (-0.71%)
JD : 27.16 (-0.98%)
BMRN : 92.42 (+1.47%)
PINS : 34.79 (+2.11%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Average short term outlook on maintaining the current direction.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Business Summary

BioMarin Pharmaceutical Inc. focuses on the development and commercialization of treatments for serious life-threatening medical conditions, mostly for children. The company's portfolio comprises seven marketed products namely, Aldurazyme, Naglazyme, Kuvan a rare genetic enzyme deficiency disorder),...

See More

Key Turning Points

3rd Resistance Point 96.10
2nd Resistance Point 94.30
1st Resistance Point 93.36
Last Price 92.42
1st Support Level 90.62
2nd Support Level 88.82
3rd Support Level 87.88

See More

52-Week High 117.77
Fibonacci 61.8% 101.82
Fibonacci 50% 96.89
Last Price 92.42
Fibonacci 38.2% 91.97
52-Week Low 76.02

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar